For Immediate Release

Duchesnay Inc. to Present a Poster on the Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness at 2018 Annual Meeting of the North American Menopause Society (NAMS)

BLAINVILLE, QC, September 12, 2018 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

The abstract titled: Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness: A phase 3, Randomized Double-Blind Placebo-Controlled Multicenter Clinical Trial, will be presented as a poster presentation on October 4, 2018, from 6:00 to 7:00 p.m. PST.

This poster will include new data related to the use of ospemifene in menopausal women with moderate to severe vaginal dryness, a symptom of vulvovaginal atrophy (VVA), a part of the genitourinary syndrome of menopause (GSM). Duchesnay is currently seeking approval for this additional indication for ospemifene and this new safety and efficacy data is currently under evaluation by the United States Food and Drug Administration.

“We are excited to share new vaginal dryness data on ospemifene at the upcoming NAMS Annual Meeting to treat this symptom of VVA, as part of the genitourinary syndrome of menopause”, affirmed Graziella Soulban, Senior Director of Medical Affairs at Duchesnay. “With an aging population and over 30 years of a woman’s life being spent post-menopause, it is increasingly important to promote a broader understanding and access to treatments that may help advance the field of women’s health in midlife and beyond.”

About Duchesnay
Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay also commercializes a broad portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information, visit www.DuchesnayUSA.com.

Contact:
Dominique Touchette
Manager, Communications,
Duchesnay, Inc.
1 877 833-7734, ext. 266
dtouchette@duchesnay.com